SCHEMBL20810026

SCHEMBL20810026

COc1ccc(-c2cc(COC(=O)c3cc(Cl)cnc3Cl)on2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.59
▸ L3MBTL1 Q9Y468 3/20 0.59
▸ SMN1; SMN2 Q16637 5/20 0.52
▸ RAB9A P51151 3/20 0.52
▸ NPC1 O15118 2/20 0.52
▸ TDP1 Q9NUW8 2/20 0.52
▸ ALDH1A1 P00352 4/20 0.50
▸ POLB P06746 3/20 0.50
▸ HTT P42858 2/20 0.50
▸ LMNA P02545 2/20 0.50
▸ CYP1A2 P05177 1/20 0.50
▸ MEN1 O00255 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ HPGD P15428 2/20 0.45
▸ NAAA Q02083 1/20 0.43
▸ DHODH Q02127 1/20 0.42
▸ CYP3A4 P08684 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ PLA2G2A P14555 1/20 0.41
▸ CA12 O43570 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20810057 0.91 SMN1; SMN2 (0.52) MAPTL3MBTL1SMN1; SMN2RAB9ANPC1
SCHEMBL20810024 0.90 SMN1; SMN2 (0.46) MAPTL3MBTL1SMN1; SMN2RAB9ANPC1
SCHEMBL20810022 0.89 MAPT (0.46) MAPTL3MBTL1SMN1; SMN2RAB9ANPC1
SCHEMBL20810018 0.89 L3MBTL1 (0.44) MAPTL3MBTL1SMN1; SMN2RAB9ANPC1
SCHEMBL20810025 0.88 RAB9A (0.46) MAPTL3MBTL1SMN1; SMN2RAB9ANPC1
SCHEMBL20810013 0.87 MAPT (0.54) MAPTL3MBTL1SMN1; SMN2RAB9ANPC1
SCHEMBL20810017 0.87 L3MBTL1 (0.43) MAPTL3MBTL1SMN1; SMN2RAB9ANPC1
SCHEMBL20810051 0.86 L3MBTL1 (0.56) MAPTL3MBTL1SMN1; SMN2RAB9ANPC1
SCHEMBL20810029 0.85 PPARD (0.44) MAPTL3MBTL1SMN1; SMN2RAB9ANPC1
SCHEMBL20810020 0.83 POLB (0.44) MAPTL3MBTL1SMN1; SMN2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190077777-A1 NICOTINIC ACID DERIVATIVES, THEIR PREPARATION AND THE USE THEREOF XIAMEN INSTITUTE OF RARE EARTH MATERIALS (CN) 2019-03-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077777-A1 NICOTINIC ACID DERIVATIVES, THEIR PREPARATION AND THE USE THEREOF H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCAR3, NAPRT MAPT 4604/4885L3MBTL1 1941/4885SMN1; SMN2 2249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback